Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Immunogenicity screening in protein drug development

19 Feb 2007

Abstract excerpt

Most therapeutic proteins in clinical trials or on the market are, to a variable extent, immunogenic. Formation of antidrug antibodies poses a risk that should be assessed during drug development, as it possibly compromises drug safety and alters pharmacokinetics. The generation of these antibodies is critically dependent on the presence of T helper cell epitopes, which have classically been identified by in...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Glycosylation and Glycoproteins Research
Share to Monoclonal and Polyclonal Antibodies Research
Share to T-cell and B-cell Immunology

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Source

Identifiers

PMID: 17309332
DOI: 10.1517/14712598.7.3.405

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 7 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Immunogenicity screening in protein drug developmentPMID 17309332Read ↗

In silico methods for immunogenicity risk assessment and human homology screening for therapeutic antibodiesSemantic proximity Read ↗

Statistical Methodology for Qualification of a Non-Clinical Risk Assessment Peptide:T Cell Proliferation Assay to Support Decision MakingSemantic proximity Read ↗

Data-driven evaluation of suitable immunogens for improved antibody selectionSemantic proximity Read ↗

Development of a strategy and computational application to select candidate protein analogues with reduced HLA binding and immunogenicity.Semantic proximity Read ↗

Recent advances in (therapeutic protein) drug developmentSemantic proximity Read ↗

High Throughput T Epitope Mapping and Vaccine DevelopmentSemantic proximity Read ↗

A structure-based engineering approach to abrogate pre-existing antibody binding to biotherapeuticsSemantic proximity Read ↗

Identification, Selection and Immune Assessment of Liver Stage CD8 T Cell Epitopes From Plasmodium falciparum.Semantic proximity Read ↗

In silico immunogenicity assessment for sequences containing unnatural amino acids: A method using existing in silico algorithm infrastructure and a vision for future enhancementsSemantic proximity Read ↗

Identifying developability risks for clinical progression of antibodies using high-throughput in vitro and in silico approachesSemantic proximity Read ↗

Towards the prediction of non-peptidic epitopesSemantic proximity Read ↗

Advances in In-silico B-cell Epitope PredictionSemantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.